Physician profile
James Patras
NPI 1811948722
$10,816.11
in general payments reported to CMS, 2019-2025
15 companies · $898 in 2025
The $898 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $897 · 2021: $1,789 · 2022: $1,961 · 2023: $1,767 · 2024: $2,283 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,238.27 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,592.12 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,589.91 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,052.57 | 2019-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $918.93 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $746.67 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $585.96 | 2023-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $568.24 | 2019-2025 | Rexulti |
| Allergan, INC. | $561.64 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $417.25 | 2020-2022 | |
| Axsome Therapeutics, INC. | $195.61 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $194.16 | 2019-2024 | Invega Sustenna, Spravato, Invega |
| E.R. Squibb & Sons, L.L.C. | $89.92 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $39.09 | 2021 | |
| Sumitomo Pharma America, INC. | $25.77 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Patras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.